WO2011109680A2 - Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide - Google Patents

Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide Download PDF

Info

Publication number
WO2011109680A2
WO2011109680A2 PCT/US2011/027131 US2011027131W WO2011109680A2 WO 2011109680 A2 WO2011109680 A2 WO 2011109680A2 US 2011027131 W US2011027131 W US 2011027131W WO 2011109680 A2 WO2011109680 A2 WO 2011109680A2
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydroisoquinoline
methylpyrrolidin
ethyl
sulfonamide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/027131
Other languages
French (fr)
Other versions
WO2011109680A3 (en
Inventor
Steven Elenbaas
Robert Allan Farr
John Michael Kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011109680(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2012052809A priority Critical patent/SG182576A1/en
Priority to EP11708374.1A priority patent/EP2556064B1/en
Priority to MX2012008422A priority patent/MX2012008422A/en
Priority to CA2787427A priority patent/CA2787427C/en
Priority to JP2012556254A priority patent/JP5927126B2/en
Priority to RU2012142310/04A priority patent/RU2012142310A/en
Priority to CN201180012335XA priority patent/CN103068815A/en
Priority to AU2011222588A priority patent/AU2011222588B2/en
Priority to PH1/2012/501499A priority patent/PH12012501499A1/en
Priority to BR112012022234A priority patent/BR112012022234A2/en
Priority to KR1020127020498A priority patent/KR101783679B1/en
Priority to MA35288A priority patent/MA34144B1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to NZ601498A priority patent/NZ601498A/en
Publication of WO2011109680A2 publication Critical patent/WO2011109680A2/en
Priority to ZA2012/05311A priority patent/ZA201205311B/en
Priority to TNP2012000361A priority patent/TN2012000361A1/en
Priority to US13/553,455 priority patent/US8748615B2/en
Priority to IL221341A priority patent/IL221341A/en
Anticipated expiration legal-status Critical
Publication of WO2011109680A3 publication Critical patent/WO2011109680A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to processes for preparing 2-(cyclohexylmethyl)-/V- ⁇ 2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, various intermediates thereto and pharmaceutically acceptable salts thereof.
  • the histamine H3 receptors are found in the central and peripheral nervous systems.
  • the administration of histamine H3 receptor ligands may influence the secretion of neurotransmitters in the brain and the periphery and thus can be useful in the treatment of several disorders, including Alzheimer's disease and other dementias, obesity, central nervous system disorders such as vigilance and sleep disorders, narcolepsy, Parkinson's disease, attention-deficit hyperactivity disorder, memory and learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, cardiovascular disorders, and gastrointestinal disorders.
  • central nervous system disorders such as vigilance and sleep disorders, narcolepsy, Parkinson's disease, attention-deficit hyperactivity disorder, memory and learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, cardiovascular disorders, and gastrointestinal disorders.
  • a number of studies in the literature have demonstrated the cognitive enhancing properties of histamine H3 receptors antagonists in rodent models (See, e.g., Giovanni et al., Behav.
  • Alzheimer's disease is the most common cause of dementia in the elderly, and is often characterized with one or more symptoms such as memory loss, confusion, irritability and aggression, mood swings, language breakdown, long-term memory loss, withdrawal of the sufferer, and loss of motor control.
  • WO2005/118547 describes a general method of synthesis which is difficult to transpose to the industrial scale for production in large quantities.
  • This method of synthesis entails reacting 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydro-isoquinoline-7- sulfonyl chloride with (+/-)-2-(2-aminoethyl)-1-methylpyrrolidine, which product is deprotected in methanol and hydrochloric acid.
  • the enantiomers are next separated by chiral chromatography.
  • the present invention makes it possible to optimize the synthesis of 2- (cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide for industrial use by avoiding the chiral chromatographic separation of the enantiomers of (+/-)-A/-[2-(1-methylpyrrolidin-2- yl)ethyl]-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide.
  • the present invention deals with the chirality issues first, allowing the coupling of 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride with enantiomerically pure (>99% ee) (-)-2- (2-aminoethyl)-1-methylpyrrolidine. In so doing, more of the 1 ,2,3,4- tetrahydroisquinoline moiety in the starting sulfonyl chloride can be incorporated into product.
  • the present invention provides a process for producing 2- (cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide and salts thereof, of high purity and in a relatively high yield suitable for use on an industrial scale.
  • synthetic intermediates for example 2- (2,2,2-trifluoroacetyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, a compound of Formula (III
  • pharmaceutically acceptable refers to those compounds, materials, compositions, carrier agents, bulking agents, solvents, diluents and other excipients which are, within the scope of sound medicinal judgment, suitable for contact with humans or other mammals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio.
  • a process of the invention for preparing 2-(cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprises:
  • a particular process of the invention for preparing 2-(cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprises:
  • Another particular process of the invention for preparing 2-(cyclohexylmethyl)-/V- ⁇ 2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprises:
  • Amine-protected N- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide is prepared in step a) from a coupling between (-)-2-(2-aminoethyl)-1-methylpyrrolidine and an amine-protected 1 ,2,3,4- tetrahydoisoquinoline-7-sulfonyl chloride, such as 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride or 1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride protected with other suitable amine-protecting groups (i.e., amine-protecting groups that are stable in acid and removable under conditions that would not cleave the sulfonamide bond).
  • suitable amine-protecting groups
  • 2-(2,2,2-trifluoroacetyl)-A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide is prepared from a coupling between (-)-2-(2-aminoethyl)-1-methylpyrrolidine and 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride in the presence of an inorganic base, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, or an organic base, such as triethylamine and the like; in an inert solvent, for example a halogenated solvent such as dichloromethane, chloroform, 1 ,2-dichloroethane, and the like, or an ethereal solvent such as f-butyl methyl ether or 2-methylt
  • one embodiment of the invention is a process for preparing 2-(2,2,2- trifluoroacetyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline- 7-sulfonamide comprising coupling 2-(2,2,2,-trifluoroacetyl)-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1 - methylpyrrolidine in the presence of a base and in an inert solvent.
  • Another embodiment of the invention is a process for preparing 2-(cyclohexylmethyl)-A/- ⁇ 2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising the step of coupling 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1- methylpyrrolidine in the presence of a base and in an inert solvent.
  • Amine-protected 1 ,2,3,4-tetrahydoisoquinoline-7-sulfonyl chloride such as 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride, may be commercially available or otherwise may be prepared according to processes known to those skilled in the art (see, for example, Blank, B.; Krog, A.J.; Weiner, G.; Pendleton, R.G. J. Med. Chem. 1980, 23, 837-840).
  • amine-protected 1 ,2,3,4-tetrahydoisoquinoline-7-sulfonyl chlorides can be prepared by reacting the amine-protected 1 ,2,3,4-tetrahydroisoquinoline with an excess of chlorosulfonic acid in a halogenated solvent such as dichloromethane, chloroform or 1.2-dichloroethane.
  • a halogenated solvent such as dichloromethane, chloroform or 1.2-dichloroethane.
  • 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride can prepared by reacting 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline with excess chlorosulfonic acid in either chloroform or dichloromethane at about 0°C to about 5°C for several hours and then at room temperature for several days.
  • step b) The deprotection of amine-protected A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, such as 2-(2,2,2-trifluoroacetyl)-A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, in step b) may be carried out using deprotection techniques known in the art.
  • the protecting group may be removed under basic conditions, for example in the presence of an inorganic base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and potassium carbonate.
  • an inorganic base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and potassium carbonate.
  • the reaction is preferably carried out in an alcohol, such as isopropanol, methanol, and the like, or combinations of water with an ethereal solvent, such as tetrahydrofuran and dioxane, and at a temperature between about 0°C and about the reflux temperature of the mixture, and, more preferably, below about 100°C.
  • one embodiment of the invention is the process for preparing A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising deprotecting 2-(2,2,2-trifluoroacetyl)-/V- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide in the presence of a base.
  • Another embodiment of the invention is the process for preparing 2-(cyclohexylmethyl)-/V- ⁇ 2- [(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising the step of deprotecting 2-(2,2,2-trifluoroacetyl)-A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide in the presence of a base.
  • Step c) involves the formation of 2-(cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2- yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide by reacting /V- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide and cyclohexanecarboxaldehyde, in the presence of a reducing agent, such as formic acid (produced by the addition of sodium or potassium formate, and the like, for example) in an organic solvent, for example an alcohol, such as ethanol, methanol, isopropanol, and the like, or a combination of water with an ethereal solvent, such as tetrahydrofuran, dioxane, and the like, or a combination of acetonitrile with water or
  • salts of 2-(cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and hydrates and solvates thereof include conventional, non-toxic salts of 2- (cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, which can be formed with either inorganic acids such as hydrochloric acid or organic acids such as benzoic acid, fumaric acid, oxalic acid and L-tartaric acid.
  • inorganic acids such as hydrochloric acid
  • organic acids such as benzoic acid, fumaric acid, oxalic acid and L-tartaric acid.
  • a pharmaceutically acceptable salt can be obtained using standard procedures well known in the art, such as by reacting the compound of Formula (I) with stoichiometric amounts or with an excess of the desired salt- forming acid in a suitable solvent or various combinations of solvents.
  • an oxalate salt can be made by dissolving the compound of Formula (I) in ethanol and adding about 1.1 equivalents of oxalic acid, and allowing the salt to form.
  • a fumarate salt is obtained.
  • the fumarate salt is a difumarate monohydrate salt.
  • the pharmaceutically acceptable salt of 2-(cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or hydrate or solvate thereof, is optionally recrystallized.
  • Suitable recrystallization solvents include, for example, isopropanol and ethanol in the presence of an antisolvent such as toluene or acetone.
  • Another aspect of the invention are the processes described above further comprising the step of formulating 2-(cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin- 2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
  • the process comprises the step of formulating 2-(cyclohexylmethyl)-A/- ⁇ 2-[(2S)-1-methylpyrrolidin-2- yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
  • the compound of Formula (V), (-)-2-(2-aminoethyl)-1-methylpyrrolidine may be prepared as outlined in Scheme 2.
  • Step 1) entails combining 2-(2-aminoethyl)-1-methylpyrrolidine with a chiral resolving agent, such as di-p-toluoyl-D-tartaric acid, in an alcohol, such as ethanol, methanol, isopropanol, and the like, and combinations thereof including combinations with water.
  • a chiral resolving agent such as di-p-toluoyl-D-tartaric acid
  • an alcohol such as ethanol, methanol, isopropanol, and the like
  • the solvent is a combination of ethanol and water.
  • the reaction is preferably performed at temperatures between about 0°C and about the reflux temperature of the mixture, and more preferably, below about 100°C.
  • Racemic 2-(2-aminoethyl)-1-methylpyrrolidine starting material is commercially available (for example, from Anichem LLC, American Custom Chemicals Inc., Acros, Aldrich) or otherwise may be prepared according to procedures well known to those skilled in the art. (See Turner, S.C.; Esbenshade, T.A.; Bennani, Y.L.; Hancock, A. A. Bioorg. Med. Chem. Lett. 2003, 73, 2131 -2135).
  • Step 2) involves removing the resolving agent by dissolving the product of step 1), for example, (-)-2-(2-aminoethyl)-1-methylpyrrolidine, 0,0'di-p-toluoyl-D-tartaric acid salt, in a two-phase mixture of a strong acid, such as concentrated HCI, HBr, H 2 S0 4 , or H3PO 4 , and a non-polar solvent, such as f-butyl methyl ether, isopropyl acetate, and the like, at temperatures between about room temperature and about 100°C.
  • a strong acid such as concentrated HCI, HBr, H 2 S0 4 , or H3PO 4
  • a non-polar solvent such as f-butyl methyl ether, isopropyl acetate, and the like, at temperatures between about room temperature and about 100°C.
  • (-)-2-(2-aminoethyl)-1-methylpyrrolidine is isolated in a
  • the acidic solution of (-)-2-(2-aminoethyl)-1-methylpyrrolidine salt is basified by the addition of a base, such as sodium hydroxide, allowing the isolation of (-)-2-(2-aminoethyl)-1-methylpyrrolidine as the distillable free base.
  • a base such as sodium hydroxide
  • a stock solution of aqueous ethanol was prepared by mixing ethanol (10370 mL) and water (2080 mL). A mixture of ⁇ , ⁇ '-di-p-tolouyl-D-tartaric acid (1624 g, 4.203 mol) and a portion of the above-described stock solution of aqueous ethanol (9050 mL) was stirred at around 65°C under a nitrogen atmosphere. Separately, racemic 2-(2- aminoethyl)-1-methylpyrrolidine (700 g, 5.35 mol) was dissolved in a portion of the aqueous ethanol stock solution (3400 mL).
  • the amine solution was then added drop- wise to the tartaric acid solution so that the temperature was maintained at about 65°C and no solids formed during the addition.
  • the reaction was held at about 65°C for no less than 30 min before being cooled to about 0°C.
  • the precipitate was collected by filtration. A stream of nitrogen was pulled through the collected solid until no longer wet.
  • the solid was recrystallized from ethanol (15950 mL)/water (2457 mL) affording the desired product as a colorless solid: 1322.4 g (44%), >99.5% ee.
  • reaction mixture was washed once with an aqueous potassium carbonate solution prepared from potassium carbonate (220 g, 1.59 mol) and water (1 L) to liberate the free base of the product. Most of the 2-methyltetrahydrofuran was removed by vacuum distillation to the minimum stirred volume and replaced with ethanol (2 L). The distillation was resumed and continued to the minimum stirred volume.
  • the precipitated KCI was removed by filtration at between 39-51 °C.
  • the reactor was rinsed with ethanol (300 mL) which in turn was used to rinse the collected KCI.
  • the ethanol filtrates were combined and returned to the reactor.
  • the reactor was heated to approximately 55°C and 2- methyltetrahydrofuran (375 mL) was added. Seed crystals of A/- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide
  • the reaction was cooled to about 25°C, and ethanol was removed by vacuum distillation and azeotropic removal with added water (280 mL).
  • the hydrochloride salt of the product was formed by the addition of concentrated hydrochloric acid (37.3 mL, 0.451 mol), and the aqueous solution was washed with isopropyl acetate (280 mL).
  • the aqueous layer was basified with a solution of potassium carbonate (92 g, 0.666 mol) in water (100 mL).
  • the aqueous alkaline solution was extracted with isopropyl acetate (460 mL).
  • the isopropyl acetate layer was washed with water (3 x 460 mL), and the isopropyl acetate was removed by vacuum distillation and replaced with SDA 3C ethanol (460 mL).
  • the resulting clear yellow-tinged solution contained 85.7 g (91 %) of 2-(cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide in 120.4 g of solution.
  • Seed crystals of 2-(cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1-methylpyrrolidin-2-yl]ethyl ⁇ -1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate can be obtained following general procedures known to those skilled in the art in view of the above- described procedure.
  • 2-(cyclohexylmethyl)-/V- ⁇ 2-[(2S)-1- methylpyrrolidin-2-yl]ethyl ⁇ -1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate can readily be prepared as described above without the use of seed crystals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.

Description

PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-/V-{2-[(2S)-1- ETHYLPYRROLIDIN-2-YL]ETHYL}-1 ,2,3,4-TETRAHYDROISOQUINOLINE-7-
SULFONA IDE FIELD OF THE INVENTION
The present invention relates to processes for preparing 2-(cyclohexylmethyl)-/V-{2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, various intermediates thereto and pharmaceutically acceptable salts thereof. BACKGROUND OF THE INVENTION
The histamine H3 receptors are found in the central and peripheral nervous systems. The administration of histamine H3 receptor ligands may influence the secretion of neurotransmitters in the brain and the periphery and thus can be useful in the treatment of several disorders, including Alzheimer's disease and other dementias, obesity, central nervous system disorders such as vigilance and sleep disorders, narcolepsy, Parkinson's disease, attention-deficit hyperactivity disorder, memory and learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, cardiovascular disorders, and gastrointestinal disorders. To illustrate, a number of studies in the literature have demonstrated the cognitive enhancing properties of histamine H3 receptors antagonists in rodent models (See, e.g., Giovanni et al., Behav. Brain Res., 1999, 104, 147-155). These reports further suggest that antagonists and/or inverse agonists could be useful for the treatment of cognitive impairments in neurological diseases such as Alzheimer's disease and related neurodegenerative disorders. Alzheimer's disease is the most common cause of dementia in the elderly, and is often characterized with one or more symptoms such as memory loss, confusion, irritability and aggression, mood swings, language breakdown, long-term memory loss, withdrawal of the sufferer, and loss of motor control.
2-(Cyclohexylmethyl)-/V-{2-[(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, which has the structure of Formula (I):
Figure imgf000003_0001
is a potent histamine H3 receptor antagonist with inverse agonist properties. A preparation and the physical properties and beneficial pharmacological properties of 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide are described in, for example, WO2005/118547 (also US2007/0105834).
WO2005/118547 describes a general method of synthesis which is difficult to transpose to the industrial scale for production in large quantities. This method of synthesis entails reacting 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydro-isoquinoline-7- sulfonyl chloride with (+/-)-2-(2-aminoethyl)-1-methylpyrrolidine, which product is deprotected in methanol and hydrochloric acid. The enantiomers are next separated by chiral chromatography. The resulting W-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}- 1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide undergoes reductive amination with cyclohexanecarboxaldehyde in the presence of a palladium catalyst. 2- (Cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide is isolated as the free base and converted to a salt.
The present invention makes it possible to optimize the synthesis of 2- (cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide for industrial use by avoiding the chiral chromatographic separation of the enantiomers of (+/-)-A/-[2-(1-methylpyrrolidin-2- yl)ethyl]-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide. The present invention deals with the chirality issues first, allowing the coupling of 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride with enantiomerically pure (>99% ee) (-)-2- (2-aminoethyl)-1-methylpyrrolidine. In so doing, more of the 1 ,2,3,4- tetrahydroisquinoline moiety in the starting sulfonyl chloride can be incorporated into product. Using the above-described synthesis, half of this material would have been discarded with the unwanted enantiomer of A/-[2-(1-methylpyrrolidin-2-yl)ethyl]- 1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide.
BRIEF SUMMARY OF THE INVENTION
Accordingly, the present invention provides a process for producing 2- (cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide and salts thereof, of high purity and in a relatively high yield suitable for use on an industrial scale.
The present invention is also directed to synthetic intermediates, for example 2- (2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, a compound of Formula (III), wherein Pg = COCF3, that are useful in the preparation of the 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide and salts thereof.
DETAILED DESCRIPTION OF THE INVENTION
Definitions and Abbreviations
As used above, and throughout the description of the invention, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings: HPLC high performance liquid chromatography
kg kilogram
L liter
mL milliliter
MTBE methyl f-butyl ether
The term "pharmaceutically acceptable" refers to those compounds, materials, compositions, carrier agents, bulking agents, solvents, diluents and other excipients which are, within the scope of sound medicinal judgment, suitable for contact with humans or other mammals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio.
A process of the invention for preparing 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprises:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with an amine-protected tetrahydroquinoline-7-sulfonyl chloride to give an amine-protected A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
b) deprotecting the amine-protected /V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide to give A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a salt thereof;
c) reductively aminating /V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide or a salt thereof with cyclohexanecarboxaldehyde to form 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d). In one aspect of the invention, processes for preparing the 2-(cyclohexylmethyl)-/V-{2- [(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt, solvate, or hydrate thereof, or a solvate or hydrate of a pharmaceutically acceptable salt and the intermediates that are useful for preparing such compounds are outlined in Scheme 1 : Scheme 1 :
Figure imgf000006_0001
(la)
(salt)
The processes for preparing 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, as outlined in Scheme 1 , comprise:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with amine-protected tetrahydroquinoline-7-sulfonyl chloride to give a compound of Formula (III), amine- protected A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide, wherein Pg represents an amine protecting group;
b) deprotecting the compound of Formula (III) to give the compound of
Formula (II), A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide or a salt thereof; c) reductively aminating the compound of Formula (II) with cyclohexanecarboxaldehyde to give a compound of Formula (I), 2-(cyclohexylmethyl)- A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide; d) optionally reacting the compound of Formula (I) with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt, or a hydrate or solvate thereof, of Formula (la), 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide addition salt; and
e) optionally recrystallizing the product of step d). A particular process of the invention for preparing 2-(cyclohexylmethyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, comprises:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with an amine-protected tetrahydroquinoline-7-sulfonyl chloride in the presence of a base to give an amine- protected A/-{2-[(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide;
b) deprotecting the amine-protected A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide under basic conditions and in a solvent selected from an alcohol and a combination of water with an ethereal solvent, to give /V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide or a salt thereof;
c) reductively aminating /V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide or a salt thereof with cyclohexanecarboxaldehyde in the presence of a reducing agent and in a solvent selected from an alcohol and a combination of water with an ethereal solvent, to form 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a hydrate or solvate thereof, with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d). Another particular process of the invention for preparing 2-(cyclohexylmethyl)-/V-{2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, comprises:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroquinoline-7-sulfonyl chloride to give 2-(2,2,2- trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline- 7-sulfonamide;
b) deprotecting 2-(2,2,2-thfluoroacetyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide to give A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a salt thereof;
c) reductively aminating A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide, or a salt thereof with cyclohexanecarboxaldehyde to form 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt, or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d). For Scheme 1 :
Amine-protected N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide is prepared in step a) from a coupling between (-)-2-(2-aminoethyl)-1-methylpyrrolidine and an amine-protected 1 ,2,3,4- tetrahydoisoquinoline-7-sulfonyl chloride, such as 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride or 1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride protected with other suitable amine-protecting groups (i.e., amine-protecting groups that are stable in acid and removable under conditions that would not cleave the sulfonamide bond). In one aspect, 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide is prepared from a coupling between (-)-2-(2-aminoethyl)-1-methylpyrrolidine and 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride in the presence of an inorganic base, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, or an organic base, such as triethylamine and the like; in an inert solvent, for example a halogenated solvent such as dichloromethane, chloroform, 1 ,2-dichloroethane, and the like, or an ethereal solvent such as f-butyl methyl ether or 2-methyltetrahydrofuran and the like; at temperatures preferably between about 0°C and ambient temperature, for example about 25°C. Accordingly, one embodiment of the invention is a process for preparing 2-(2,2,2- trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline- 7-sulfonamide comprising coupling 2-(2,2,2,-trifluoroacetyl)-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1 - methylpyrrolidine in the presence of a base and in an inert solvent. Another embodiment of the invention is a process for preparing 2-(cyclohexylmethyl)-A/-{2- [(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising the step of coupling 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1- methylpyrrolidine in the presence of a base and in an inert solvent.
Amine-protected 1 ,2,3,4-tetrahydoisoquinoline-7-sulfonyl chloride, such as 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride, may be commercially available or otherwise may be prepared according to processes known to those skilled in the art (see, for example, Blank, B.; Krog, A.J.; Weiner, G.; Pendleton, R.G. J. Med. Chem. 1980, 23, 837-840). For example, amine-protected 1 ,2,3,4-tetrahydoisoquinoline-7-sulfonyl chlorides can be prepared by reacting the amine-protected 1 ,2,3,4-tetrahydroisoquinoline with an excess of chlorosulfonic acid in a halogenated solvent such as dichloromethane, chloroform or 1.2-dichloroethane. In particular, 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride can prepared by reacting 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline with excess chlorosulfonic acid in either chloroform or dichloromethane at about 0°C to about 5°C for several hours and then at room temperature for several days. Quenching of the reaction into a mixture of chloroform or dichloromethane and crushed ice affords a solution of the desired sulfonyl chloride, which following removal of the solvent, can be purified by crystallization from, for example, f-butyl methyl ether. The deprotection of amine-protected A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, such as 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, in step b) may be carried out using deprotection techniques known in the art. Preferably, the protecting group may be removed under basic conditions, for example in the presence of an inorganic base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and potassium carbonate. The reaction is preferably carried out in an alcohol, such as isopropanol, methanol, and the like, or combinations of water with an ethereal solvent, such as tetrahydrofuran and dioxane, and at a temperature between about 0°C and about the reflux temperature of the mixture, and, more preferably, below about 100°C.
Therefore, one embodiment of the invention is the process for preparing A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising deprotecting 2-(2,2,2-trifluoroacetyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide in the presence of a base. Another embodiment of the invention is the process for preparing 2-(cyclohexylmethyl)-/V-{2- [(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising the step of deprotecting 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide in the presence of a base.
Step c) involves the formation of 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide by reacting /V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide and cyclohexanecarboxaldehyde, in the presence of a reducing agent, such as formic acid (produced by the addition of sodium or potassium formate, and the like, for example) in an organic solvent, for example an alcohol, such as ethanol, methanol, isopropanol, and the like, or a combination of water with an ethereal solvent, such as tetrahydrofuran, dioxane, and the like, or a combination of acetonitrile with water or an alcohol with water. This reaction is preferably performed at temperatures between about 0°C and about the reflux temperature of the mixture, and, more preferably, below about 100°C.
Pharmaceutically acceptable salts of 2-(cyclohexylmethyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and hydrates and solvates thereof, include conventional, non-toxic salts of 2- (cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, which can be formed with either inorganic acids such as hydrochloric acid or organic acids such as benzoic acid, fumaric acid, oxalic acid and L-tartaric acid. A pharmaceutically acceptable salt can be obtained using standard procedures well known in the art, such as by reacting the compound of Formula (I) with stoichiometric amounts or with an excess of the desired salt- forming acid in a suitable solvent or various combinations of solvents. For example, an oxalate salt can be made by dissolving the compound of Formula (I) in ethanol and adding about 1.1 equivalents of oxalic acid, and allowing the salt to form. In one aspect of the invention, a fumarate salt is obtained. In a preferred aspect, the fumarate salt is a difumarate monohydrate salt.
The pharmaceutically acceptable salt of 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or hydrate or solvate thereof, is optionally recrystallized. Suitable recrystallization solvents include, for example, isopropanol and ethanol in the presence of an antisolvent such as toluene or acetone.
Another aspect of the invention are the processes described above further comprising the step of formulating 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin- 2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients. In one aspect, the process comprises the step of formulating 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients. The compound of Formula (V), (-)-2-(2-aminoethyl)-1-methylpyrrolidine, may be prepared as outlined in Scheme 2.
Scheme 2:
Figure imgf000012_0001
For Scheme 2:
Step 1) entails combining 2-(2-aminoethyl)-1-methylpyrrolidine with a chiral resolving agent, such as di-p-toluoyl-D-tartaric acid, in an alcohol, such as ethanol, methanol, isopropanol, and the like, and combinations thereof including combinations with water. Preferably, the solvent is a combination of ethanol and water. The reaction is preferably performed at temperatures between about 0°C and about the reflux temperature of the mixture, and more preferably, below about 100°C.
Racemic 2-(2-aminoethyl)-1-methylpyrrolidine starting material is commercially available (for example, from Anichem LLC, American Custom Chemicals Inc., Acros, Aldrich) or otherwise may be prepared according to procedures well known to those skilled in the art. (See Turner, S.C.; Esbenshade, T.A.; Bennani, Y.L.; Hancock, A. A. Bioorg. Med. Chem. Lett. 2003, 73, 2131 -2135).
Step 2) involves removing the resolving agent by dissolving the product of step 1), for example, (-)-2-(2-aminoethyl)-1-methylpyrrolidine, 0,0'di-p-toluoyl-D-tartaric acid salt, in a two-phase mixture of a strong acid, such as concentrated HCI, HBr, H2S04, or H3PO4, and a non-polar solvent, such as f-butyl methyl ether, isopropyl acetate, and the like, at temperatures between about room temperature and about 100°C. In one aspect, (-)-2-(2-aminoethyl)-1-methylpyrrolidine is isolated in aqueous solution as a salt. In another aspect, the acidic solution of (-)-2-(2-aminoethyl)-1-methylpyrrolidine salt is basified by the addition of a base, such as sodium hydroxide, allowing the isolation of (-)-2-(2-aminoethyl)-1-methylpyrrolidine as the distillable free base.
The following examples present typical syntheses as described in Schemes 1 and 2. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. Example 1
Preparation of compound of Formula (VI): (-)-2-(2-Aminoethyl)-1-methylpyrrolidine, 0,0 -Di-p-toluoyl-D-tartaric acid salt
A stock solution of aqueous ethanol was prepared by mixing ethanol (10370 mL) and water (2080 mL). A mixture of Ο,Ο'-di-p-tolouyl-D-tartaric acid (1624 g, 4.203 mol) and a portion of the above-described stock solution of aqueous ethanol (9050 mL) was stirred at around 65°C under a nitrogen atmosphere. Separately, racemic 2-(2- aminoethyl)-1-methylpyrrolidine (700 g, 5.35 mol) was dissolved in a portion of the aqueous ethanol stock solution (3400 mL). The amine solution was then added drop- wise to the tartaric acid solution so that the temperature was maintained at about 65°C and no solids formed during the addition. The reaction was held at about 65°C for no less than 30 min before being cooled to about 0°C. The precipitate was collected by filtration. A stream of nitrogen was pulled through the collected solid until no longer wet. The solid was recrystallized from ethanol (15950 mL)/water (2457 mL) affording the desired product as a colorless solid: 1322.4 g (44%), >99.5% ee.
Example 2
Preparation of compound of Formula (V): (-)-2-(2-Aminoethyl)-1-methylpyrrolidine A solution of HCI (296 mL, 3.55 mol) and water (517 mL) was added to a mixture of (- )-2-(2-aminoethyl)-1-methylpyrrolidine, 0, 0 -di-p-toluoyl-D-tartaric acid salt (900 g, 1.75 mol) and MTBE (3.2 L). After stirring for 45 minutes, the layers were separated. Additional MTBE (1.6 L) was added to the aqueous layer. After stirring for about 10 minutes, the layers were separated. With stirring, 50% aqueous NaOH (476 mL, 9.19 mol) was added to the aqueous acid layer over about 35 minutes. The mixture was stirred for about 35 minutes, then cooled to 10°C. The organic layer was separated and distilled at reduced pressure to provided 206 g (92%) of the desired product.
Example 3
Preparation of compound of Formula (III): 2-(2,2,2-Trifluoroacetyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide A solution of (-)-2-(2-aminoethyl)-1 -methylpyrrolidine (172 g, 1 .345 mol) in water (400 mL) was prepared and added to a solution of 2-(2,2,2-trifluoroacetyl)-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride (400 g, 1.22 mol) in 2- methyltetrahydrofuran (1600 mL) at a controlled rate to maintain the reaction temperature between -5°C and 5°C. Upon completion of the coupling, the reaction mixture was washed once with an aqueous potassium carbonate solution prepared from potassium carbonate (220 g, 1.59 mol) and water (1 L) to liberate the free base of the product. Most of the 2-methyltetrahydrofuran was removed by vacuum distillation to the minimum stirred volume and replaced with ethanol (2 L). The distillation was resumed and continued to the minimum stirred volume. The ethanolic solution of 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide was diluted with ethanol (1 132 mL) to obtain a 30 wt % solution of product, assuming a 97% yield, and carried forward into the next step. Example 4
Preparation of a compound of Formula (II): A/-{2-[(2S)-1-Methylpyrrolidin-2-yl]ethyl}- 1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide Dihydrochloride Sesquihydrate
A 45.7% solution of potassium hydroxide (105 g, 0.855 mol) was added to a 30.66% (w/w) ethanolic solution of 2-(2,2,2-trifluoroacetyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide (1023.6, 0.748 mol) at a rate that limited the temperature to no more than 45°C. After cooling to room temperature, the reaction was monitored by HPLC. Upon completion of the deprotection, the reaction was acidified by the dropwise addition of concentrated hydrochloric acid (194 mL, 2.35 mol). The precipitated KCI was removed by filtration at between 39-51 °C. The reactor was rinsed with ethanol (300 mL) which in turn was used to rinse the collected KCI. The ethanol filtrates were combined and returned to the reactor. The reactor was heated to approximately 55°C and 2- methyltetrahydrofuran (375 mL) was added. Seed crystals of A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide
dihydrochloride sesquihydrate (1 g) were added. After cooling to approximately -5°C, the product was collected by filtration. The product was rinsed with a solution prepared from 2-methyltetrahydrofuran (200 mL), ethanol (200 mL) and water (5 mL). Following drying in a vacuum oven at 40°C, 277 g (87%) of W-{2-[(2S)-1 - methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide
dihydrochloride sesquihydrate was isolated as a colorless solid. Seed crystals of W-{2-[(2S)-1-Methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide dihydrochloride sesquihydrate can be obtained following general procedures known to those skilled in the art. Alternatively, N-{2- [(2S)-1 -Methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide dihydrochloride sesquihydrate can readily be prepared as described above without the use of seed crystals.
Example 5
Preparation of a compound of Formula (I): 2-(Cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide
A/-{2-[(2S)-1-Methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide dihydrochloride sesquihydrate (92 g, 0.217 mol) was reacted with potassium formate (33.6 g, 0.399 mol) and cyclohexanecarboxaldehyde (39 mL, 0.322 mol) in hot SDA 3C ethanol (460 mL). The reaction vessel was heated to about 72°C, with release of C02. The reaction mixture was monitored for completion by HPLC. Upon completion, the reaction was cooled to about 25°C, and ethanol was removed by vacuum distillation and azeotropic removal with added water (280 mL). The hydrochloride salt of the product was formed by the addition of concentrated hydrochloric acid (37.3 mL, 0.451 mol), and the aqueous solution was washed with isopropyl acetate (280 mL). The aqueous layer was basified with a solution of potassium carbonate (92 g, 0.666 mol) in water (100 mL). The aqueous alkaline solution was extracted with isopropyl acetate (460 mL). The isopropyl acetate layer was washed with water (3 x 460 mL), and the isopropyl acetate was removed by vacuum distillation and replaced with SDA 3C ethanol (460 mL). The resulting clear yellow-tinged solution contained 85.7 g (91 %) of 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide in 120.4 g of solution.
Example 6
Preparation of a Compound of Formula (la): 2-(Cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate
A solution of 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide (532 g, 1.27 mol) in SDA 3C ethanol (1056 mL) was added to a suspension of fumaric acid (302 g, 2.60 mol) in water (624 mL). The resulting solution was diluted with acetone (4 L) then cooled and seeded with milled 2-(cyclohexylmethyl)-W-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate (4.2 g). After seeding, the mixture was stirred to allow crystal growth then further diluted with acetone (1990 mL). After cooling, the product was collected by filtration and washed with acetone (1.500 L). Filtration was conducted by portionwise loading of acetone into the filter- dryer. After loading of each portion of acetone (1.5L), stirring was turned on at 2.6 rpm to ensure good contact between product and acetone. The product was dried in a vacuum oven at 40°C with nitrogen purge and vacuum (residual pressure 400 mBar), then allowed to re-hydrate at room temperature in the air to yield 684.7 g (85.8 %) of 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate.
Seed crystals of 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate can be obtained following general procedures known to those skilled in the art in view of the above- described procedure. Alternatively, 2-(cyclohexylmethyl)-/V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate can readily be prepared as described above without the use of seed crystals.

Claims

CLAIMS What is claimed is:
1. A process for preparing 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt comprising:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with an amine-protected tetrahydroquinoline-7-sulfonyl chloride to give an amine-protected A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
b) deprotecting the amine-protected A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide to give /V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a salt thereof;
c) reductively aminating A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide or a salt thereof with cyclohexanecarboxaldehyde to form 2-(cyclohexylmethyl)-A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a hydrate or solvate thereof, with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d). 2. The process according to claim 1 , wherein the amine-protected tetrahydroquinoline-7-sulfonyl chloride is 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonyl chloride and the amine-protected /V-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide is 2-(2,2,2- trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,
2,3,4-tetrahydroisoquinoline- 7-sulfonamide.
3. The process according to claim 1 , wherein the coupling in step a) is performed in the presence of an inorganic or organic base and in an inert solvent.
4. The process according to claim 3, wherein the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide and triethylamine.
5. The process according to claim 1 , wherein deprotecting in step b) is performed under basic conditions and in an alcohol.
6. The process according to claim 1 , wherein the reductive amination of step c) is performed in an organic solvent in the presence of a reducing agent.
7. The process according to claim 6, wherein the reducing agent is formic acid.
8. The process according to claim 1 , wherein the salt formed in step d) is a pharmaceutically acceptable salt.
9. The process according to claim 1 , further comprising formulating 2- (cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of a pharmaceutically acceptable salt, with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
10. The process according to claim 1 , wherein the salt-forming acid in step d) is fumaric acid to provide 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate.
1 1. The process according to claim 10, further comprising formulating 2- (cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
12. The process according to claim 1 , comprising:
a) coupling (-)-2-(2-aminoethyl)-1 -methylpyrrolidine with 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroquinoline-7-sulfonyl chloride to give 2-(2,2,2- trifluoroacetyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline- 7-sulfonamide;
b) deprotecting 2-(2,2,2-trifluoroacetyl)-/V-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide to give A/-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, or a salt thereof;
c) reductively aminating A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide, or a salt thereof with cyclohexanecarboxaldehyde to form 2-(cyclohexylmethyl)-A/-{2-[(2S)-1 - methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt, or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d).
13. The process according to claim 12, further comprising formulating 2- (cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt, or a solvate or hydrate of a pharmaceutically acceptable salt, with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
14. The process according to claim 12, wherein the salt-forming acid in step d) is fumaric acid to provide 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate.
15. The process according to claim 14, further comprising formulating 2- (cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate with one or more pharmaceutically acceptable carrier agents, bulking agents, solvents, diluents and other excipients.
16. The process according to claim 1 , comprising:
a) coupling (-)-2-(2-aminoethyl)-1-methylpyrrolidine with an amine-protected tetrahydroquinoline-7-sulfonyl chloride in the presence of a base to give an amine- protected A/-{2-[(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide;
b) deprotecting the amine-protected A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfona under basic conditions and in a solvent selected from an alcohol and a combination of water with an ethereal solvent, to give A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7- sulfonamide or a salt thereof;
c) reductively aminating A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide or a salt thereof with cyclohexanecarboxaldehyde in the presence of a reducing agent and in a solvent selected from an alcohol and a combination of water with an ethereal solvent, to form 2-(cyclohexylmethyl)-/V-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 , 2,3,4- tetrahydroisoquinoline-7-sulfonamide;
d) optionally reacting 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide with a stoichiometric amount or an excess of a salt-forming acid in a solvent to form a salt or a hydrate or solvate thereof; and
e) optionally recrystallizing the product of step d).
17. The compound 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide.
18. A process for preparing 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin- 2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide comprising coupling 2-(2,2,2- trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2- aminoethyl)-1-methylpyrrolidine in the presence of a base and in an inert solvent.
19. A process for preparing 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, comprising the step of coupling 2-(2,2,2-trifluoroacetyl)-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonyl chloride and (-)-2-(2-aminoethyl)-1-methylpyrrolidine in the presence of a base and in an inert solvent.
20. A process for preparing W-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide comprising deprotecting 2-(2,2,2- trifluoroacetyl)-A/-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline- 7-sulfonamide in the presence of a base.
21. A process for preparing 2-(cyclohexylmethyl)-A/-{2-[(2S)-1-methylpyrrolidin-2- yl]ethyl}-1 ,2,3,4-tetrahydroisoquinoline-7-sulfonamide, comprising the step of deprotecting 2-(2,2,2-trifluoroacetyl)-A/-{2-[(2S)-1 -methylpyrrolidin-2-yl]ethyl}-1 ,2,3,4- tetrahydroisoquinoline-7-sulfonamide in the presence of a base.
PCT/US2011/027131 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide Ceased WO2011109680A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
NZ601498A NZ601498A (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{ 2-[(2s)-1-methylpyrrolidin-2-yl]ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
KR1020127020498A KR101783679B1 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
MX2012008422A MX2012008422A (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide.
CA2787427A CA2787427C (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
JP2012556254A JP5927126B2 (en) 2010-03-05 2011-03-04 Process for producing 2- (cyclohexylmethyl) -N- {2-[(2S) -1-methylpyrrolidin-2-yl] ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
RU2012142310/04A RU2012142310A (en) 2010-03-05 2011-03-04 METHOD FOR PRODUCING 2- (CYCLOHEXYLMETHYL) -N- {2 - [(2S) -1-METHYLPYRROLIDIN-2-YL] ETHYL} -1,2,3,4-TETHYRHOISOCHINOLIN-7-SULFONAMIDE
CN201180012335XA CN103068815A (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
AU2011222588A AU2011222588B2 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-N-{2- [(2S)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
PH1/2012/501499A PH12012501499A1 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
SG2012052809A SG182576A1 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
MA35288A MA34144B1 (en) 2010-03-05 2011-03-04 PROCESS FOR THE PREPARATION OF 2- (CYCLOHEXYLMETHYL) -N- {2 - [(2S) -1-METHYLYLYRYLIDIN-2-YL] ETHYL} -1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE
EP11708374.1A EP2556064B1 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
BR112012022234A BR112012022234A2 (en) 2010-03-05 2011-03-04 Process for the preparation of 2- (cyclohexylmethyl) -n- {2 - {(2s) -1-methylpyrrolidin-2-yl] ethyl} -1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
TNP2012000361A TN2012000361A1 (en) 2010-03-05 2012-07-17 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
ZA2012/05311A ZA201205311B (en) 2010-03-05 2012-07-17 Process for the preparation of 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
US13/553,455 US8748615B2 (en) 2010-03-05 2012-07-19 Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
IL221341A IL221341A (en) 2010-03-05 2012-08-07 Process for Preparation of 2- (Cyclohexylmethyl) -one- {2 - [(2As) -1-Methylpyrrolidine-2-Ill] Ethyl} -1,2,3,4-Tetrahydroisoquinoline-7-Sulphonamide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
US61/311,069 2010-03-05
FR1059750 2010-11-25
FR1059750 2010-11-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/553,455 Continuation US8748615B2 (en) 2010-03-05 2012-07-19 Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide

Publications (2)

Publication Number Publication Date
WO2011109680A2 true WO2011109680A2 (en) 2011-09-09
WO2011109680A3 WO2011109680A3 (en) 2012-12-20

Family

ID=44012569

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2011/027118 Ceased WO2011109675A2 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
PCT/US2011/027131 Ceased WO2011109680A2 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027118 Ceased WO2011109675A2 (en) 2010-03-05 2011-03-04 Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide

Country Status (28)

Country Link
US (2) US8748615B2 (en)
EP (2) EP2542530A2 (en)
JP (2) JP5927126B2 (en)
KR (2) KR20130047685A (en)
CN (2) CN103221394A (en)
AR (2) AR080375A1 (en)
AU (2) AU2011223560A1 (en)
BR (2) BR112012022234A2 (en)
CA (2) CA2787427C (en)
CL (2) CL2012002452A1 (en)
CO (2) CO6630129A2 (en)
CR (1) CR20120467A (en)
DO (1) DOP2012000228A (en)
EC (1) ECSP12012207A (en)
GT (1) GT201200228A (en)
IL (2) IL221339A0 (en)
MA (2) MA34144B1 (en)
MX (2) MX2012008422A (en)
NZ (2) NZ601498A (en)
PE (1) PE20130007A1 (en)
PH (2) PH12012501499A1 (en)
RU (2) RU2012142310A (en)
SG (2) SG182576A1 (en)
TN (1) TN2012000361A1 (en)
TW (2) TW201144285A (en)
UY (2) UY33262A (en)
WO (2) WO2011109675A2 (en)
ZA (1) ZA201205311B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748615B2 (en) 2010-03-05 2014-06-10 Sanofi Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816101A (en) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 Synthesis method of (S)-N-methyl-2 chloro-ethyl-pyrrolidine
CN105764510A (en) * 2013-09-09 2016-07-13 赛诺菲 An H3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN111417634A (en) * 2017-10-04 2020-07-14 细胞基因公司 Process for the preparation of cis-4- [2- { [ (3S,4R) -3-fluorooxan-4-yl ] amino } -8- (2,4, 6-trichloroanilino) -9H-purin-9-yl ] -1-methylcyclohexane-1-carboxamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118547A1 (en) 2004-05-25 2005-12-15 Sanofi-Aventis Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
WO1994029273A1 (en) 1993-06-09 1994-12-22 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
PL343424A1 (en) 1998-04-10 2001-08-13 Japan Tobacco Inc Amidine compounds
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CA2347095A1 (en) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
AR025884A1 (en) 1999-10-01 2002-12-18 Takeda Pharmaceutical CYCLINE AMINE COMPOUNDS, ITS PRODUCTION AND USE
WO2001040192A1 (en) 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
FR2804429B1 (en) 2000-01-31 2003-05-09 Adir NOVEL 4-SULFONAMIDE PIPERIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR2807434B1 (en) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc NOVEL 1,2,3,4-TETRAHYDROISOQUINOLEIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS FUNGICIDES
KR100823908B1 (en) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, or 5-substituted-N1- (benzenesulfonyl) indole and its therapeutic use
EP1339677B1 (en) * 2000-10-30 2006-01-04 Warner-Lambert Company LLC Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
JP2004532834A (en) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー Non-imidazole arylalkylamine compounds that are histamine H3 receptor antagonists, their production and therapeutic use
WO2002102770A1 (en) * 2001-06-18 2002-12-27 Maruha Corporation Novel aliphatic compound, method of synthesis, and method of utilization
US20050043304A1 (en) 2001-08-01 2005-02-24 Yutaka Kato Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
FR2857695B1 (en) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches BLOCK FOR FILTRATION OF PARTICLES CONTAINED IN THE EXHAUST GASES OF AN INTERNAL COMBUSTION ENGINE
US20070117797A1 (en) 2004-01-02 2007-05-24 Goble Stephen D Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
US7410961B2 (en) 2004-01-20 2008-08-12 Merck & Co., Inc. 2,6-disubstituted piperiddines as modulators
JP2007534756A (en) 2004-04-26 2007-11-29 メルク　エンド　カムパニー　インコーポレーテッド Tetrahydropyranylcyclopentyltetrahydropyridopyridine modulators of chemokine receptor activity
EP1742919A4 (en) 2004-04-26 2010-04-28 Merck Sharp & Dohme CYCLOPENTYL TETRAHYDROISOQUINOLINE 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROPYRANYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
BRPI0510665A (en) 2004-05-11 2007-12-04 Incyte Corp 3- (4-heteroarylcycloexylamino) cyclopentane carboxyamides as chemokine receptor modulators
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
ES2257168B1 (en) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. 5-HT7 RECEIVER LIGANDS.
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP2311827A1 (en) 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
SE0403086D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
ES2325035T3 (en) 2004-12-21 2009-08-24 Smithkline Beecham Corporation ERBB QUINASE INHIBITORS OF 2-PYRIMIDINYL PYRAZOLOPIRIDINE.
CA2592092A1 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
ATE447572T1 (en) 2005-01-26 2009-11-15 Hoffmann La Roche PHENYLMETHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER-1 INHIBITORS
DE102005015040A1 (en) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament
AR053845A1 (en) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-TIAZOLILMETIL [(1S, 2R) -3 - [[(2-AMINO-6-BENZOXAZOLIL) SULFONIL)] (2-METHYLPROPIL) AMINO] -2-HYDROXY-1- (PHENYLMETIL) PROPIL] CARBAMATE AS A PHARMACY IMPROVER METABOLIZED BY THE CYCROCHROME P450
MX2007014180A (en) 2005-05-10 2008-01-14 Vertex Pharma Bicyclic derivatives as modulators of ion channels.
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
WO2008136378A1 (en) 2007-04-27 2008-11-13 Toyama Chemical Co., Ltd. Novel sulfonamide derivative and salt thereof
WO2009127822A2 (en) 2008-04-16 2009-10-22 Biolipox Ab Bis-aryl compounds for use as medicaments
WO2010127272A2 (en) 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
EP2445899B1 (en) 2009-06-26 2016-05-11 Sanofi Novel fumarate salts of a histamine h3 receptor antagonist
AR080375A1 (en) 2010-03-05 2012-04-04 Sanofi Aventis PROCEDURE FOR THE PREPARATION OF 2- (CYCLOHEXIMETHYL) -N- {2 - [(2S) -1-METHYLPIRROLIDIN-2-IL] ETIL} -1,2,3,4-TETRAHYDROISOCHINOLINE- 7-SULFONAMIDE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118547A1 (en) 2004-05-25 2005-12-15 Sanofi-Aventis Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
US20070105834A1 (en) 2004-05-25 2007-05-10 Sanofi-Aventis Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLANK, B.; KROG, A.J.; WEINER, G.; PENDLETON, R.G., J. MED. CHEM., vol. 23, 1980, pages 837 - 840
GIOVANNI ET AL., BEHAV. BRAIN RES., vol. 104, 1999, pages 147 - 155
TURNER, S.C.; ESBENSHADE, T.A.; BENNANI, Y.L.; HANCOCK, A.A., BIOORG. MED. CHEM. LETT., vol. 13, 2003, pages 2131 - 2135

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748615B2 (en) 2010-03-05 2014-06-10 Sanofi Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
US8779145B2 (en) 2010-03-05 2014-07-15 Sanofi Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline

Also Published As

Publication number Publication date
CN103221394A (en) 2013-07-24
UY33262A (en) 2011-09-30
CA2789669A1 (en) 2011-09-09
DOP2012000228A (en) 2013-01-15
AU2011223560A1 (en) 2012-09-13
AU2011222588B2 (en) 2016-09-08
US20130137718A1 (en) 2013-05-30
IL221341A0 (en) 2012-10-31
RU2012142338A (en) 2014-04-10
IL221339A0 (en) 2012-10-31
TN2012000361A1 (en) 2014-01-30
KR20130038186A (en) 2013-04-17
MX2012009413A (en) 2012-09-07
JP2013521308A (en) 2013-06-10
PE20130007A1 (en) 2013-02-01
US8779145B2 (en) 2014-07-15
TW201144285A (en) 2011-12-16
TW201144284A (en) 2011-12-16
NZ601498A (en) 2014-12-24
AU2011222588A1 (en) 2012-08-23
RU2012142310A (en) 2014-04-10
ZA201205311B (en) 2013-03-27
IL221341A (en) 2014-05-28
PH12012501641A1 (en) 2012-10-22
EP2542530A2 (en) 2013-01-09
CA2787427C (en) 2017-10-10
SG182576A1 (en) 2012-08-30
WO2011109675A2 (en) 2011-09-09
CA2787427A1 (en) 2011-09-09
MX2012008422A (en) 2012-08-15
CR20120467A (en) 2012-10-05
BR112012022234A2 (en) 2015-12-15
PH12012501499A1 (en) 2018-02-07
ECSP12012207A (en) 2013-03-28
US20130123302A1 (en) 2013-05-16
WO2011109680A3 (en) 2012-12-20
JP2013521309A (en) 2013-06-10
CL2012002451A1 (en) 2012-11-30
BR112012022356A2 (en) 2016-08-30
US8748615B2 (en) 2014-06-10
CO6630099A2 (en) 2013-03-01
SG183256A1 (en) 2012-09-27
GT201200228A (en) 2013-11-21
CO6630129A2 (en) 2013-03-01
CN103068815A (en) 2013-04-24
UY33263A (en) 2011-09-30
AR080374A1 (en) 2012-04-04
JP5927126B2 (en) 2016-05-25
KR20130047685A (en) 2013-05-08
NZ602009A (en) 2015-01-30
EP2556064B1 (en) 2014-10-15
KR101783679B1 (en) 2017-10-10
MA34142B1 (en) 2013-04-03
MA34144B1 (en) 2013-04-03
AR080375A1 (en) 2012-04-04
WO2011109675A3 (en) 2012-11-22
CL2012002452A1 (en) 2012-11-30
EP2556064A2 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
WO2008065500A2 (en) Heteroaryl amides as type i glycine transport inhibitors
JP6873053B2 (en) Method for Producing Protein Deacetylation Inhibitor
KR102295388B1 (en) A novel synthetic route for the production of optically active diamine derivative and thiazole derivate
AU2011222588B2 (en) Process for the preparation of 2-(cyclohexylmethyl)-N-{2- [(2S)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
JP7182562B2 (en) Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
US20130116441A1 (en) Intermediates and process for preparing a thrombin specific inhibitor
WO2014009964A1 (en) Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide
RS65238B1 (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
CN103012264B (en) The method for splitting of 3 substituted-amino hexahydro 1H azepans
KR20210010487A (en) Intermediates and methods for the preparation of linagliptin and salts thereof
RU2741389C1 (en) Method for preparing intermediate compound for synthesis of medicinal agent
EA049781B1 (en) METHOD FOR PRODUCING AVAPRITINIB AND ITS INTERMEDIATES
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
JP2009508961A (en) Production method of amino acid derivatives
IE20000060A1 (en) Novel Process for Producing AMPA Antagonist Compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180012335.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11708374

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2787427

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/008422

Country of ref document: MX

Ref document number: DZP2012000525

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 12012501499

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011222588

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20127020498

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6859/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 221341

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2011222588

Country of ref document: AU

Date of ref document: 20110304

Kind code of ref document: A

Ref document number: 0164912

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2012002451

Country of ref document: CL

Ref document number: 2012556254

Country of ref document: JP

Ref document number: 001391-2012

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201004494

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2011708374

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2012-000467

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: A201211502

Country of ref document: UA

Ref document number: 12174787

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2012142310

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012022234

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012022234

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120903